The tissue-specific metabolic effects of the PPARα agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study.
Vera H W de WitFroukje VanweertJuho R H RaikoViktor LiénardGert SchaartAnne GemminkEmmani B M NascimentoMatthijs K C HesselinkJoachim E WildbergerRoel WiertsPeter J JorisJoel HaasDavid MontaigneBart StaelsEsther PhielixPatrick SchrauwenVera B Schrauwen-HinderlingTineke van de WeijerPublished in: Obesity (Silver Spring, Md.) (2023)
Ciprofibrate treatment increased hepatic lipid accumulation and lowered MRgluc, without affecting whole-body insulin sensitivity. Furthermore, parameters of cardiac function or cardiac energy status were not altered upon ciprofibrate treatment.